Logos Global Management’s Immuneering IMRX Stock Holding History

Logos Global Management’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-950,000	Closed	-$6.65M	–	76
2025 Q3	$6.65M	Buy	+950,000	New	+$4.93M	0.6%	43

Other funds holding IMRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Logos Global Management's IMRX Position: Q4 2025 in Review

Logos Global Management sold out of Immuneering (IMRX) in Q4 2025, closing a stake of 950,000 shares — an estimated $6.65M sold.

Logos Global Management first reported a position in IMRX in Q3 2025 and held it in 1 quarter. The position peaked at $6.65M in Q3 2025. 86 funds tracked by Wall St. Rank hold IMRX as of Q4 2025.

Logos Global Management reported no remaining Immuneering position as of Q4 2025 after selling out during the quarter.
Logos Global Management sold 950,000 Immuneering shares in Q4 2025, an estimated $6.65M.
Logos Global Management first reported a position in Immuneering in Q3 2025 and held it in 1 quarter.
Logos Global Management's Immuneering position peaked at $6.65M in Q3 2025.
86 funds tracked by Wall St. Rank held Immuneering as of Q4 2025.

Based on Logos Global Management's 13F filing for Q4 2025, filed 17 Feb 2026.